ReviewFrontiers in pharmacology2022

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations.

Wenliang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.